Replies to post #165631 on Biotech Values

[mcbio]

IDRA

May 8... reported P2 results on TLR antagonist IMO-3100 for moderate to severe psoriasis...

Clinical Activity:
On day 57, 48% of patients treated with either dose of IMO-3100 (12 of 25) demonstrated statistically significant improvements of 35% to 90% from baseline PASI scores compared with 0 of 12 in the placebo cohort (p<0.005)

ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887&highlight=

Results sound promising on the surface but on a few of the endpoints there is an inverted dose response curve. For example, reduction in PASI score at day 29 was stat sig at lower dose but not at higher dose. Same with improvement in induration. Does this make results more likely to be a fluke?

I will say that the fact that DVAX is generally operating in this space (TLR7,8,9 for autoimmune) does add some validity to what they're doing I suppose. But, there have been a lot of failures with TLRs over the years. Why should we believe IDRA will succeed here? Also, why is IDRA not proceeding further apparently with IMO-3100 and instead proceeding with just IMO-8400? I realize the latter hits all of TLR7,8,9 and the former just hits TLR7,9 but you would think with these "positive" results they would want to run another trial with 3100. Finally, are there prior results in the clinic for these TLR7,8,9 agonists in autoimmune setting? I need to go back and research all the prior failures from IDRA and DVAX to see if it was specifically in this setting and with this specific MoA.